Corbus Pharmaceuticals Holdings, Inc.
CRBPCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare, inflammatory, and fibrotic diseases. The company's pipeline emphasizes its expertise in cannabinoid-based medicines, with particular interest in conditions such as cystic fibrosis, dermatomyositis, and other inflammatory disorders. Corbus aims to deliver novel treatments targeting underlying disease mechanisms to improve patient outcomes.
Company News
Corbus Pharmaceuticals announced that CEO Yuval Cohen will present a corporate overview and participate in investor meetings at the RBC Capital Markets Global Healthcare Conference (May 19-20, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The clinical-stage company is developing CRB-701, an antibody drug conjugate for Nec...
Corbus Pharmaceuticals announced FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with a registrational study expected to launch this summer. The company completed enrollment in its CANYON-1 Phase 1b study of CRB-913 for obesity treatment with topline data expected summer 2026. Q1 20...
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage oncology and obesity company, announced that CEO Yuval Cohen will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company's pipeline includes CRB-701 (antibody drug conjugate)...
Corbus Pharmaceuticals has priced a public offering of 4,744,231 common stock shares and pre-funded warrants, raising approximately $75 million to fund clinical development and corporate purposes.
Corbus Pharmaceuticals plans to raise approximately $75 million through a public offering of 4,744,231 common stock shares and pre-funded warrants, with proceeds intended to fund clinical development and working capital.
